TAE Technologies Partners with Japan’s Institute for Fusion Science (NIFS) for Fusion Fuel Research

TAE Technologies Partners with Japan’s Institute for Fusion Science (NIFS) for Fusion Fuel Research

TAE Technologies, the world’s largest private fusion energy company, today announced a landmark partnership with Japan’s National Institute for Fusion Science (NIFS) that enables the two organizations to test the effects of hydrogen-boron (p-B11) fusion reactions in the NIFS Large Helical Device (LHD). The results of this research have the potential to unlock a new milestone in TAE’s mission to develop commercial fusion power with p-B11, the cleanest and most affordable fuel for fusion cycles.

TAE Technologies Commercializes Breakthrough Power Management Technology Developed for Fusion to Revolutionize Electric Vehicles, Charging Infrastructures, and Energy Storage

TAE Technologies Commercializes Breakthrough Power Management Technology Developed for Fusion to Revolutionize Electric Vehicles, Charging Infrastructures, and Energy Storage

TAE Technologies, the world’s largest private fusion energy company, announces the formation of its TAE Power Management division, that will bring disruptive power management capabilities originally developed for the company’s fusion power control systems to the mobility and energy storage sectors. Veteran industrialist David Roberts has been named Chief Executive Officer of the rapidly growing division. He will report to TAE Group CEO Michl Binderbauer.

TAE Technologies Expands Executive Team with William Coaker as Chief Investment Officer

TAE Technologies Expands Executive Team with William Coaker as Chief Investment Officer

TAE Technologies is pleased to announce the appointment of William Coaker as the company’s first Chief Investment Officer. Bill comes to TAE with over two decades of experience in investment, most recently as Chief Investment Officer for the San Francisco Employees Retirement System (SFERS), a $34 billion public pension plan. Bill’s leadership and vision will play a central role in TAE’s next phase of growth.

TAE Life Sciences secures $30M in initial B round to accelerate development of unique boron delivery drugs for novel cancer treatment, boron neutron capture therapy (BNCT).

TAE Life Sciences secures $30M in initial B round to accelerate development of unique boron delivery drugs for novel cancer treatment, boron neutron capture therapy (BNCT).

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company’s initial funding in 2018.